Molecular Devices Becomes Global Distributor of IonFlux
News May 28, 2013
Molecular Devices® announced it has made an agreement with Fluxion Biosciences to become global distributor for the IonFlux™ portfolio of instrumentation and consumables. Molecular Devices will also provide support for all IonFlux Systems users through its recently expanded team of Application Specialists.
The IonFlux Systems offer an unrivalled level of simplicity for electrophysiology. Combined with low running costs, this makes the systems an ideal solution for laboratories in both academic and industrial settings. The IonFlux 16 Electrophysiology System is capable of delivering results from up to 64 test compounds per run, while the IonFlux HT Platform can deliver results from up to 256 test compounds per run.
Jeff Jensen, CEO of Fluxion, commented: “Molecular Devices’ long history in the electrophysiology field, combined with the expertise of its applications support team, means that they are ideally placed to support scientists working with IonFlux Systems. We are delighted that they will be taking responsibility for distributing the line worldwide.”
Kevin Chance, President of Molecular Devices, said: “The IonFlux Systems are an excellent complement to our existing line of electrophysiology products, which includes IonWorks Barracuda® and IonWorks Quattro™ Automated Systems with Population Patch Clamp™ Technology, PatchXpress® 7000A and the Axon® line of Conventional Electrophysiology Systems. The simplicity of the IonFlux Systems enables a broad range of scientists to access electrophysiology and ion channel research, making them a great addition to the Molecular Devices offering.
New Drug to Treat Herpes Simplex Virus Infection?News
Researchers have now identified a small drug molecule that can clear the HSV-1 infection in the cells of the cornea -- the clear outer layer of the eyeball -- and works completely differently than the currently-available drugs, making it a promising potential option for patients who have developed resistance.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Gaining a Deeper Understanding of Protein Kinases Involved in CancerNews
Vaccinia-related protein kinases VRK1 and VRK2, which are involved in cell proliferation, are considered potential targets for treatment of prostate, ovarian, colorectal and other kinds of cancer. To obtain a deeper understanding of the role of these enzymes in human cells, in the contexts of both wellness and disease, researchers are working on the development of small synthetic molecules capable of modulating their activity in study models.READ MORE